Cargando…
Evaluating the impact of glucokinase activation on risk of cardiovascular disease: a Mendelian randomisation analysis
BACKGROUND: Glucokinase activators (GKAs) are an emerging class of glucose lowering drugs that activate the glucose-sensing enzyme glucokinase (GK). Pending formal cardiovascular outcome trials, we applied two-sample Mendelian randomisation (MR) to investigate the impact of GK activation on risk of...
Autores principales: | Wang, Ke, Shi, Mai, Huang, Chuiguo, Fan, Baoqi, Luk, Andrea O. Y., Kong, Alice P. S., Ma, Ronald C. W., Chan, Juliana C. N., Chow, Elaine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503210/ https://www.ncbi.nlm.nih.gov/pubmed/36151532 http://dx.doi.org/10.1186/s12933-022-01613-6 |
Ejemplares similares
-
Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes
por: Chow, Elaine, et al.
Publicado: (2023) -
Human Serum Metabolites as Potential Mediators from Type 2 Diabetes and Obesity to COVID-19 Severity and Susceptibility: Evidence from Mendelian Randomization Study
por: Huang, Chuiguo, et al.
Publicado: (2022) -
Age- and sex-specific hospital bed-day rates in people with and without type 2 diabetes: A territory-wide population-based cohort study of 1.5 million people in Hong Kong
por: Wu, Hongjiang, et al.
Publicado: (2023) -
Lifetime risk of developing diabetes in Chinese people with normoglycemia or prediabetes: A modeling study
por: Zhang, Xinge, et al.
Publicado: (2022) -
Glucose-lowering drug use, glycemic outcomes, and severe hypoglycemia: 18-Year trends in 0·9 million adults with Diabetes in Hong Kong (2002–2019)
por: Yang, Aimin, et al.
Publicado: (2022)